TimesSquare Capital Management LLC Boosts Position in Mirum Pharmaceuticals, Inc. $MIRM

TimesSquare Capital Management LLC increased its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 31.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 395,827 shares of the company’s stock after acquiring an additional 95,178 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Mirum Pharmaceuticals were worth $31,266,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in MIRM. MCF Advisors LLC lifted its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter. Quarry LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $41,000. Finally, CWM LLC grew its position in shares of Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. HC Wainwright set a $185.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $136.42.

Mirum Pharmaceuticals Stock Down 6.5%

Shares of NASDAQ:MIRM opened at $95.49 on Tuesday. The stock has a market cap of $5.82 billion, a P/E ratio of -7.02 and a beta of 0.52. The firm has a fifty day moving average price of $95.52 and a 200 day moving average price of $87.79. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals, Inc. has a 1-year low of $42.89 and a 1-year high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Insider Activity

In related news, COO Peter Radovich sold 16,515 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the completion of the sale, the chief operating officer owned 40,272 shares in the company, valued at $3,704,218.56. This represents a 29.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eric Bjerkholt sold 7,287 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the sale, the chief financial officer owned 49,788 shares of the company’s stock, valued at approximately $4,579,500.24. This represents a 12.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 76,806 shares of company stock worth $7,064,616 over the last 90 days. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.